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ABSTRACT
An increasing incidence of nosocomial infections caused by non-multiresistant methicillin-resistant
Staphylococcus aureus (nMMRSA) has been reported worldwide. The present study genotyped nMMRSA
isolates obtained from hospitals in two cities in Brazil. The hospital isolates displayed pulsed-ﬁeld gel
electrophoresis (PFGE) patterns that were similar to those of the USA100 (ST5-SCCmecII) and USA 800
(ST5-SCCmecIV) strains, which are related to the New York ⁄ Japan and paediatric clones, respectively.
Carriage of SCCmecIV and the classiﬁcation by multilocus sequence typing (MLST) of a representative of
this PFGE pattern in clonal complex 5 (CC5) conﬁrmed the genetic relationship of the Brazilian isolates
with USA800. The USA800-related Brazilian isolates were responsible for severe nosocomial infections
in compromised adults and elderly patients in Brazil. A higher growth rate, an ability to form bioﬁlm on
inert polystyrene surfaces and the presence of the egc locus may have contributed, at least in part, to the
ﬁtness of these organisms as global nosocomial pathogens.
Keywords Clonal complex 5, methicillin-resistant Staphylococcus aureus, paediatric clone, pulsed-ﬁeld gel
electrophoresis, SCCmecIV, USA800
Original Submission: 13 February 2007; Revised Submission: 30 May 2007; Accepted: 15 July 2007
Clin Microbiol Infect 2007; 13: 1165–1172
INTRODUCTION
Methicillin-resistant Staphylococcus aureus
(MRSA) infections currently pose a signiﬁcant
threat worldwide. MRSA is one of the most
well-adapted and widespread nosocomial
pathogens, representing a major cause of
invasive disease among hospitalised individuals
in many countries [1]. Consequently, MRSA
infections have been associated with increased
morbidity and mortality among patients in
hospitals [2,3]. Generally, hospital-associated
MRSA (HA-MRSA) isolates display a high level
of multiresistance [4], which may result in
inappropriate empirical therapy, delay in the
prescription of effective antimicrobial drugs,
and the use of less effective, more toxic and
expensive antimicrobial agents. Methicillin
resistance in staphylococci is determined by
the staphylococcal cassette chromosome mec
(SCCmec) element carrying the mecA gene,
which encodes the altered penicillin-binding
protein 2A or 2¢ that confers cross-resistance to
all b-lactam antibiotics [5].
Based mainly on analysis according to pulsed-
ﬁeld gel electrophoresis (PFGE), SCCmec typing
and multilocus sequence typing (MLST), several
lineages of pandemic HA-MRSA have been
deﬁned, including the so-called Iberian clone
(USA500-related; ST247-SCCmecIA), the Brazilian
epidemic clone (BEC; ST239-SCCmecIIIA), the
New York ⁄ Japan clone (USA100-related;
ST5-SCCmecII), the paediatric clone (USA800-
related; ST5-SCCmecIV or ST5-SCCmecVI) and
the EMRSA-16 clone (USA200; ST36-SCCmecII)
[1,6,7]. In Brazil, isolates belonging to the BEC
have disseminated and predominated in hospi-
tals throughout the country [8–10]. BEC isolates
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have also been detected in other countries in
South America, Europe and Asia [11–18]. More
recently, USA800-related isolates colonising the
noses of healthcare workers in Rio de Janeiro,
Brazil have been detected [19]. Isolates related to
USA800 (paediatric clone) were ﬁrst detected by
Sa-Lea˜o et al. [20] in a paediatric hospital in
Lisbon, but have also caused HA infections in
other countries, including the USA, Poland,
Argentina, Colombia, Spain and France [21–25].
Until 1998, the BEC was the predominant clone
reported in Cordoba (43%) and other regions of
Argentina, but it began to be displaced progres-
sively by an MRSA clone related to USA800 in
1999 [23].
Five types of SCCmec, and their derivatives,
have been described, based on the ccr gene
complex (harbouring the recombinase genes)
and the mec gene complex (harbouring the mecA
and mec regulatory genes) [5]. More recently,
Oliveira et al. [26] proposed that the SCCmecIV
element carried by paediatric isolates from Por-
tugal should be renamed as SCCmecVI, as it had
the new allotype 4, while the paediatric-related
isolates from other countries studied had allo-
type 2. Although SCCmecI, SCCmecII, SCCmecIII,
SCCmecIV and SCCmecVI have been detected
among HA-MRSA isolates, the majority of
community-acquired MRSA (CA-MRSA) isolates
harbour SCCmecIV or SCCmecV [26–28]. As has
been generally veriﬁed for strains carrying
SCCmecIV, SCCmecV or SCCmecVI, USA800 iso-
lates display a broad spectrum of antimicrobial
susceptibilities [27,28], while BEC isolates are
frequently multiresistant [8].
Following the detection of USA800-related
isolates colonising healthcare workers in Rio de
Janeiro [19], the present study searched for these
isolates as a cause of nosocomial infection in
Brazil, which is a country that has previously
been dominated by infections caused by the
BEC. In addition, several virulence traits that
might be important for the establishment of this
emerging clone in Brazilian hospitals were
investigated.
MATERIALS AND METHODS
Bacterial isolates
MRSA isolates were obtained from two university hospitals
located in the northeast and southeast regions of Brazil,
separated by a distance of c. 2800 km, in which the inci-
dence of MRSA is c. 55–60%. In total, 81 HA-MRSA isolates
were studied, 43 of which were from a university general
hospital located in Recife (north-east Brazil) during 2002–
2003. The remaining 38 HA-MRSA isolates were from a
university paediatric hospital located in Rio de Janeiro
(south-east Brazil) during 2005. Single isolates were obtained
from infected or colonised patients. The isolates were
conﬁrmed as MRSA by PCR ampliﬁcation of an internal
fragment of the mecA gene [29] and by the conventional free
coagulase test.
Four additional isolates of USA800 (HC476, HC568, HC653
and HC753) from healthcare workers [19] were used for the
detection of accessory genes. HC568 was also used for pattern
comparisons in PFGE experiments. The prototypes of the
USA100 clone, and the USA300 and USA400 CA-MRSA clones
[7] (kindly supplied by P. Dunman, University of Nebraska,
NE, USA), were used in some PFGE experiments. Additional,
well-characterised isolates representing international lineages
of MRSA, i.e., BMB9393 (BEC), WB69 and RO930 (CA-MRSA
representative of the Oceania Southwest Paciﬁc clone—OSPC),
and NY17859 (USA100), were from our own laboratory
collection. Finally, isolate GV69 (BEC) was used in the analysis
of bacterial generation times.
Susceptibility tests
Disk-diffusion tests were performed according to CLSI rec-
ommendations [30], using disks containing the following
antimicrobial agents: ciproﬂoxacin (5 lg), clindamycin (2 lg),
chloramphenicol (30 lg), erythromycin (15 lg), gentamicin
(10 lg), linezolid (30 lg), mupirocin (5 lg), oxacillin (1 lg),
rifampicin (5 lg), trimethoprim–sulphamethoxazole (125 lg ⁄
23.75 lg), tetracycline (30 lg) and vancomycin (30 lg). S. aur-
eus ATCC 25923 was used for quality control purposes. The
MLSBi phenotype (inducible macrolide, lincosamide and
streptogramin B resistance) was detected by D test as de-
scribed previously [31]. Vancomycin resistance was also tested
by growing strains in brain–heart infusion broth containing
vancomycin 6 mg ⁄L [32], with S. aureus ATCC 25923 as a
susceptible control and Enterococcus faecalis ATCC 51575 as a
resistant control.
Molecular characterisation
Full molecular characterisation (SCCmec typing, PFGE and
MLST) was performed for the isolates from Recife, as the
molecular epidemiology of nosocomial infections caused by
MRSA in this city was unknown. In Rio de Janeiro hospitals,
MRSA isolates belonging to the BEC account for c. 80% of all
MRSA isolates [8,33]; thus, PFGE experiments were performed
only for those isolates from Rio de Janeiro that did not harbour
SCCmecIIIA (characteristic of BEC isolates). PFGE of SmaI-
digested DNA was performed in a CHEF-DR III system (Bio-
Rad, Richmond, CA, USA) as described previously [10]. The
visual criteria used for interpreting the PFGE results were
those of Tenover et al. [34]. PFGE patterns were also compared
using Molecular Analyst Fingerprinting Plus software v.1.12
(Image Analysis System; Bio-Rad) with the Dice coefﬁcient and
UPGMA clustering.
SCCmec typing was performed using the PCR multiplex
methods described previously [26,29].
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MLST typing followed the procedures and recommenda-
tions described on the MLST website (http://www.mlst.net).
Detection of accessory genes
DNA was puriﬁed using phenol ⁄ chloroform extraction as
described previously [35], except that the bacterial cells were
lysed with 100 U of lysostaphin (Sigma, St Louis, MO, USA).
The DNA was used in standard PCRs (with the sets of
primers listed in Table S1, see Supplementary material) in a
GeneAmp 9700 Thermocycler (Perkin-Elmer Cetus, Warring-
ton, UK). Ampliﬁcation comprised 94C for 4 min, followed
by 30 cycles of 94C for 30 s, 55C for 30 s and 72C for
1 min 30 s, with a ﬁnal extension at 72C for 4 min and
cooling to 4C.
Detection of bioﬁlm production
Bioﬁlm production was detected using trypticase soy broth
(Difco Laboratories, Detroit, MI, USA) supplemented with
glucose 1%w ⁄v.Aliquots (200 lL) of overnight cultures diluted
1:100 were dispensed in sterile 96-well ﬂat-bottomed tissue
culture plates (Nunclon; Nunc A ⁄ S, Roskilde, Denmark). All
procedures were performed as described by Amaral et al. [36],
with Staphylococcus epidermidis 70D and Streptococcus pyogenes
75194 as positive and negative controls, respectively. Bioﬁlm
productionwas expressed relative to the results obtained for the
negative control, with a bioﬁlm unit (BU) calculated as
describedpreviously [36]. Bioﬁlmproduction for Strep. pyogenes
was calculated as 0.115 BU. Thus, S. aureus isolates producing
£0.230 BU were deﬁned as non-producers, those producing
0.230–0.460 BU as weak producers, those producing 0.460–
0.920 BU as moderate producers, and those producing
>0.920 BU as strong producers. Because bioﬁlm production is
subject to phase variation, at least two independent assays were
carried out with four repeat measurements of each sample. The
highest BU value obtained in each independent experiment was
used for the statistical calculations, according to the null
hypothesis (ANOVA test). When bioﬁlm production was
negative, three additional experiments with four duplicate
measurements each were performed.
Bacterial growth rate
Isolates AM771 (an isolate related to USA800, obtained in the
present study from a catheter site infection) and GV69 (a BEC
isolate obtained from a case of pneumonia) [36] were used in
this experiment. Overnight trypticase soy broth cultures were
diluted to an OD600 nm of 0.025 in 200 mL of fresh broth in a
500-mL Erlenmeyer ﬂask. The cultures were then incubated
at 37C with shaking at 225 rpm. In initial experiments, two
aliquots were collected from each culture at intervals of 30–
60 min for viable count determinations. A growth curve was
then plotted to determine the exponential phase. The exper-
iment was then repeated as above, except that aliquots were
collected only during the exponential phase, at 30-min
intervals, for viable count determinations. The mean values
of the results obtained from two independent experiments
were plotted, and the data from the exponential growth
phase were then analysed to determine the bacterial growth
rate according to a linear regression model (Origin v.7.0;
Origin Lab Corp., Northampton, MA, USA) using the
Pearson product moment correlation (r).
RESULTS
Molecular analysis
Using the criteria of Tenover et al. [34], 29 (67%)
of the 43 MRSA isolates from Recife had PFGE
proﬁles (pattern A) similar to the BEC, as they
differed by no more than six PFGE bands from
isolate BMB9393 (Fig. S1A, see Supplementary
material). These isolates were found to carry
SCCmecIIIA (Table 1). Of the 14 remaining MRSA
isolates from Recife, six (14%) had PFGE ﬁnger-
print patterns (pattern B) that differed from BEC
isolate BMB9393 by more than six PFGE bands
(Fig. S1B), but which were quite similar to that of
the USA800 clone (isolate HC568; Fig. S1D) and
the USA100 clone (clone NY17859; Fig. S1D). Five
different B patterns were detected among Recife
isolates (Table 1). In addition, it was found that all
isolates from Recife with pattern B carried
SCCmecIV, allotype 2 (Table 1). The remaining
eight isolates from Recife (PFGE patterns C–J)
differed from BMB9393 and the isolates repre-
senting the USA100 and USA800 clones by more
than six bands, and also from the representatives
of the CA-MRSA clones circulating in the Amer-
ican Continent (Fig. S1C).
Subsequently, in order to verify whether the
USA800 isolates were also causing nosocomial
infection in Rio de Janeiro, 34 MRSA isolates
obtained in a university paediatric hospital were
analysed. Of these, three (9%) had PFGE patterns
similar to those of the USA100 and USA800 clones
(Fig. S1D). Isolates IP09 and IP17 had identical
PFGE patterns (B7), while isolate IP34 had a
variant pattern (B8). As expected for Rio de Janeiro
hospitals [8,33], all of the remaining isolates
carried SCCmecIIIA. Fig. S1E shows that the
USA800 and USA100 prototypes and the B-pattern
MRSA from Brazil were clustered together. In
addition, the MRSA isolates from Recife with
pattern A and the BEC isolate BMB9393 clustered
together in a separate part of the dendogram.
Detection of SCCmecIV, allotype 2, in isolates
IP09 and IP17 conﬁrmed that these MRSA isolates
were related to the USA800 clone. However,
isolate IP34 carried SCCmecII, as did the isolates
from the USA100 clone. A representative with
PFGE pattern B and SCCmecIV (AM771) was
selected for MLST analysis. The allelic proﬁle
obtained (1–4–1–4–12–1–10) indicated that AM771
belonged to clonal complex ST5 (CC5). Thus,
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MRSA isolates with PFGE patterns similar to the
USA100 and USA800 clones, carrying SCCmecIV
and belonging to ST5, are related to the USA800
clone.
The mean age of the six patients from Recife
who were infected by USA800 isolates was
76.5 years (range 44–80 years), while the two
patients from the Rio de Janeiro hospital were
aged 3 and 8 years, respectively. The patients
were all severely ill and presented with different
co-morbidities.
Antimicrobial resistance
As expected, the isolates from Recife belonging
to the BEC displayed a high level of multiresis-
tance. In contrast, all the isolates related to the
USA800 clone were resistant to only one
antibiotic besides b-lactams (Table 1), and were
susceptible to choramphenicol, gentamicin,
linezolid, mupirocin, rifampicin, trimethoprim–
sulphamethoxazole and vancomycin. Three of
the USA800 isolates (AM642, AM771 and
Table 1. Clinical origin, resistance proﬁle and pulsed-ﬁeld gel electrophoresis (PFGE) patterns of methicillin-resistant
Staphylococcus aureus isolates from two hospitals located in Recife and Rio de Janeiro, Brazil
Isolatea Isolation date Clinical origin Resistance proﬁleb PFGE typingc SCCmec typing
AM517 1 ⁄ 25 ⁄ 2002 Skin infection CIP, GEN, OXA, SXT, TET, ERY A13 IIIA
AM519 1 ⁄ 28 ⁄ 2002 Colonisation CIP, GEN, OXA, SXT, TET, ERY A13 IIIA
AM528 2 ⁄ 18 ⁄ 2002 Surgical site infection CIP, GEN, OXA, SXT, TET, ERY A4 IIIA
AM548 3 ⁄ 7 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A1 IIIA
AM574 3 ⁄ 25 ⁄ 2002 Colonisation GEN, OXA, SXT, PEN C ND
AM588 4 ⁄ 8 ⁄ 2002 Surgical site infection CIP, GEN, OXA, SXT, TET, ERY A1 IIIA
AM594 4 ⁄ 15 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, ERY A13 IIIA
AM599 4 ⁄ 17 ⁄ 2002 Skin infection OXA, ERY B3 IV, allotype 2
AM631 5 ⁄ 3 ⁄ 2002 Catheter insertion site infection CIP, GEN, OXA, SXT, TET, ERY A14 IIIA
AM642 9 ⁄ 5 ⁄ 2002 Skin infection OXA, ERY, CLId B5 IV, allotype 2
AM651 5 ⁄ 17 ⁄ 2002 Catheter insertion site infection CIP, GEN, OXA, SXT, TET, ERY A1 IIIA
AM716 7 ⁄ 11 ⁄ 2002 Colonisation CIP, GEN, OXA,SXT, TET, ERY A1 IIIA
AM771 8 ⁄ 23 ⁄ 2002 Catheter insertion site infection OXA, ERY,CLId B3 IV, allotype 2
AM791 9 ⁄ 5 ⁄ 2002 Catheter insertion site infection CIP, GEN, OXA, SXT, TET, ERY A9 IIIA
AM795 9 ⁄ 9 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A9 IIIA
AM798 9 ⁄ 9 ⁄ 2002 Colonisation CIP, GEN, OXA, SXT, TET, ERY A12 IIIA
AM799 9 ⁄ 9 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A1 IIIA
AM833 10 ⁄ 21 ⁄ 2002 Surgical site infection CIP, GEN, OXA, SXT, TET, ERY A2 IIIA
AM834 10 ⁄ 21 ⁄ 2002 Pneumonia CLO, OXA F ND
AM836 10 ⁄ 22 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, ERY J ND
AM837 10 ⁄ 23 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A8 IIIA
AM841 10 ⁄ 30 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A1 IIIA
AM858 11 ⁄ 27 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A7 IIIA
AM860 12 ⁄ 27 ⁄ 2002 Bloodstream infection OXA, ERY,CLId B2 IV, allotype 2
AM868 11 ⁄ 7 ⁄ 2002 Bloodstream infection CIP, GEN, OXA, SXT, ERY E ND
AM869 1 ⁄ 14 ⁄ 2003 Surgical infection CIP, GEN, OXA, SXT, TET, ERY A1 IIIA
AM872 1 ⁄ 27 ⁄ 2003 Urinary tract infection OXA, TET G ND
AM874 02 ⁄ 07 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A11 IIIA
AM875 02 ⁄ 13 ⁄ 2003 Bloodstream infection OXA, ERY D ND
AM876 02 ⁄ 18 ⁄ 2003 Bloodstream infection OXA I ND
AM895 03 ⁄ 10 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A5 IIIA
AM898 03 ⁄ 13 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A7 IIIA
AM902 03 ⁄ 17 ⁄ 2003 Catheter insertion site infection CIP, GEN, OXA, SXT, TET, ERY A3 IIIA
AM905 03 ⁄ 19 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A9 IIIA
AM912 03 ⁄ 26 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A1 IIIA
AM920 04 ⁄ 01 ⁄ 2003 Bloodstream infection CIP, OXA, SXT, TET, ERY H ND
AM922 04 ⁄ 03 ⁄ 2003 Skin infection CIP, OXA B4 IV, allotype 2
AM923 04 ⁄ 03 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A6 IIIA
AM932 04 ⁄ 08 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A9 IIIA
AM942 04 ⁄ 23 ⁄ 2003 Bloodstream infection OXA,TET B6 IV, allotype 2
AM948 05 ⁄ 07 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A10 IIIA
AM952 05 ⁄ 08 ⁄ 2003 Peritonitis CIP, GEN, OXA, SXT, TET, ERY A10 IIIA
AM953 05 ⁄ 15 ⁄ 2003 Bloodstream infection CIP, GEN, OXA, SXT, TET, ERY A10 IIIA
IP09 04 ⁄ 11 ⁄ 2005 Colonisation OXA B7 IV, allotype 2
IP17 04 ⁄ 14 ⁄ 2005 Colonisation ERY, OXA B7 IV, allotype 2
IP34 05 ⁄ 20 ⁄ 2005 Colonisation CIP, GEN, OXA, SXT, TET, ERY B8 II
aAM isolates were from Recife and IP isolates were from Rio de Janeiro.
bAntimicrobial agents tested were ciproﬂoxacin 5 lg (CIP), clindamycin 2 lg (CLI), chloramphenicol 30 lg (CHL), erythromycin 15 lg (ERY), gentamicin 10 lg (GEN),
linezolid 30 lg (LZD), mupirocin 5 lg (MUP), oxacillin 1 lg (OXA), rifampicin 5 lg (RIF), trimethoprim–sulphamethoxazole 125 lg ⁄ 23.75 lg (SXT), tetracycline 30 lg (TET)
and vancomycin 30 lg (VAN).
cPFGEs were carried out using SmaI-digested DNA. PFGE patterns were analysed using the criteria described by Tenover et al. [34]. Isolates of PFGE pattern A were compared
with a representative of the Brazilian epidemic clone (BMB9393) and an isolate of pattern B was compared with a representative of the USA800 clone (HC568). The sporadic
patterns were compared with all international MRSA clones used in this study.
dThe isolate displayed an MLSBi phenotype (macrolide, lincosamide, streptogramin B inducible resistance).
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AM860) showed inducible resistance to clinda-
mycin (MLSBi phenotype), as they formed a zone
in D tests.
Of the three MRSA isolates obtained from Rio
de Janeiro with pattern B, the two USA800-related
isolates (IP09 and IP17) had a resistance proﬁle
very similar to that of the USA800 isolates from
Recife, whereas isolate IP34, related to the
USA100 clone, displayed resistance to six anti-
microbial agents (ciproﬂoxacin, clindamycin,
erythromycin, gentamicin, tetracycline and
trimethoprim–sulphamethoxazole), in addition
to b-lactams (Table 1).
Bacterial growth rate
Using the linear regression model, log CFU ⁄
mL = A + B*t, where A is the initial inoculum, B
is the bacterial culture growth rate and t is time
(h), the data for the representative USA800
(AM771) and BEC (GV69) isolates revealed that
the USA800 isolate had a growth rate of 0.4 ⁄h, as
compared with 0.2 ⁄h for the BEC isolate.
Bioﬁlm production
Bioﬁlm production was determined for 16 MRSA
isolates, comprising six USA800 isolates from the
present study, four well-characterised USA800
isolates from our own laboratory collection [19],
and six isolates belonging to the BEC from
inpatients at the university hospital in Recife.
The USA800 isolates yielded a mean value of
0.3 BU and were classiﬁed as weak bioﬁlm pro-
ducers. In addition, two USA800 isolates were
non-bioﬁlm producers (Table 2). In contrast, the
BEC isolates yielded a mean value of 1 BU (strong
bioﬁlm producers). The difference in bioﬁlm
production for the USA800 and BEC isolates
was statistically signiﬁcant (p <0.0001).
Detection of accessory genes
The MRSA isolates that were analysed from the
USA800 and BEC clones carried the lukE–lukD
genes, encoding the LukED leukocidin (except
BEC isolate AM905; Table 2). However, none of
the isolates was positive for the LukM leukocidin
gene or for the F component of Panton–Valentine
leukocidin. No genes for the superantigens SEA,
SEB, SED, SEJ, SEH, SEK and SEL, or the staph-
ylococcal epidermal cell differentiation inhibitor,
were detected. The USA800 isolates studied har-
boured the enterotoxin gene cluster (egc) locus,
and one isolate (AM860) also carried sec, but none
of these enterotoxin genes was detected among
MRSA isolates belonging to the BEC (Table 2).
DISCUSSION
This molecular characterisation of 81 MRSA
isolates from two hospitals located in different
regions of Brazil was performed in order to
investigate the emergence of USA800 isolates as
nosocomial pathogens in Brazil. The data showed
that the BEC was the most common MRSA strain
recovered from the university general hospital
located in Recife, accounting for c. 70% of the
MRSA isolates analysed. It has been demon-
strated previously that BEC isolates have
acquired advantageous properties (e.g., enhanced
ability to produce bioﬁlm and to adhere to and
invade airway epithelial cells) that might play a
role in their emergence as a successful interna-
tional nosocomial MRSA clone [36]. However,
14% (6 ⁄ 43) of the MRSA isolates from Recife were
USA800-related, as were 5.9% (2 ⁄ 34) of the
isolates from Rio de Janeiro. The latter were from
colonised patients, but the six isolates from Recife
were involved in either localised or disseminated
infections.
Vivoni et al. [33] reported the detection of two
ST5-SCCmecIV MRSA isolates in a collection of 34
MRSA isolates obtained from a university general
hospital in Rio de Janeiro during 1999–2000, but
these isolates were not compared with interna-
tional MRSA clones. Many other studies have
reported an increasing incidence of HA-MRSA
that harbour SCCmecIV and display susceptibility
to multiple non-b-lactam antimicrobial agents in
various countries in Europe and America [16,37–
40]. Denis et al. [38] reported an increase in such
MRSA isolates, from 22% to 48%, between 1995
and 1997–1998 in Belgian hospitals. Similarly,
Trindade et al. [37] found that 13% of the MRSA
isolates collected from infants in a general
hospital in Sa˜o Paulo, Brazil, during 2004 were
non-multiresistant MRSA (nMMRSA) isolates car-
rying SCCmecIV. Although these latter isolates
were not fully characterised, their PFGE patterns
[37] appear to be identical to that of isolate
HC568, indicating that USA800-related isolates
are also causing nosocomial infections in Sa˜o
Paulo.
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The increasing incidence of such isolates in
different countries does not support the theory
that multiresistance is the only factor involved in
the success of a speciﬁc MRSA clone. It is
possible that USA800 isolates might have partic-
ular characteristics that promote their emergence
as important international hospital pathogens.
Thus, the USA800 isolate tested had a two-fold
increase in growth rate compared with the BEC
isolate tested. Similar results were reported by
Laurent et al. [41], who suggested that the non-
multiresistant phenotype would represent a ﬁt-
ness advantage, and demonstrated that an
nMMRSA isolate was able to rapidly overgrow
a multiresistant MRSA isolate [41], thereby sug-
gesting a link among genetic patterns, resistance
proﬁles and growth abilities for S. aureus clinical
isolates [41,42]. It has also been suggested that
isolates carrying SCCmecIV may have some
ﬁtness advantages because this element carries
only the structural and regulatory genes for
methicillin resistance and the recombinase genes
for the mobility of the mec cassette [28]. In
contrast, SCCmecIIIA carries additional genes,
e.g., those encoding resistance to non-b-lactam
antibiotics and heavy metals.
The ﬁrst reported cases of the USA800-related
paediatric clone in a hospital involved neonatal
patients [20], and Trindade et al. [37] also
observed that the majority of hospital infections
caused by nMMRSA carrying SCCmecIV
occurred in a neonatal intensive care unit.
However, in the present study, all patients
infected with the USA800 clone were adults or
elderly patients with a combination of co-mor-
bidities. The immune system of such patients is
frequently impaired, facilitating bacterial host
colonisation and spread. In this context, isolates
related to the USA800 clone could represent a
particular threat.
The egc locus encodes enterotoxins SEG, SEI,
SEM, SEN and SEO, known as the enterotoxin
gene cluster, and may be associated with staphyl-
ococcal toxic shock syndrome and scarlet fever
[42]. It is interesting that recent MLST studies
have revealed that successful staphylococcal
clones usually harbour the egc locus [43]. The
egc locus was also detected in MRSA clones
belonging to CC5 that were isolated in Lyon,
France [44].
Isolates from the BEC were classiﬁed as strong
bioﬁlm producers, but USA800 isolates only
displayed weak production. Nevertheless,
although BEC isolates are superior in their ability
to produce bioﬁlm [36], the ability of some
USA800 isolates to cause catheter-associated
infection was not impaired in three of the patients
in the present study or, as reported by Trindade
et al. [37], in neonates.
Another signiﬁcant feature of some MRSA
isolates is the heterogeneous expression of meth-
icillin resistance [45,46], and a previous study has
indicated that the heterogeneous proﬁle of
USA800-related isolates increases the chance of
misdiagnosing these MRSA strains [47]. In addi-
tion, the broad spectrum of susceptibility to non-
b-lactam antibiotics, in contrast to the high-level
multiresistance of the predominant BEC, may also
inﬂuence the misidentiﬁcation of USA800 isolates
in Brazil.
In conclusion, the emergence of the USA800
MRSA lineage should be carefully monitored, as
USA800 isolates seem to cause infections prefer-
entially in very compromised patients for whom
the introduction of prompt and effective anti-
microbial therapy is imperative. A number of
characteristics, e.g., SCCmecIV, non-multiresis-
tance, the egc locus and bioﬁlm production,
may have contributed, at least in part, to the
increasing worldwide emergence of this MRSA
clone as a nosocomial agent. Further studies are
required to elucidate the dynamics involved in
Table 2. Bioﬁlm production and accessory genes carried
by methicillin-resistant Staphylococcus aureus isolates
belonging to the USA800 paediatric clone and the Brazilian
epidemic clone (BEC)
Isolates Clone
Bioﬁlma
unitsa Phenotypeb egcc sec lukED
AM599 USA800 0.40 Weak + ) +
AM642 USA800 0.3 Weak + ) +
AM771 USA800 0.39 Weak + ) +
AM860 USA800 0.27 Weak + + +
AM922 USA800 0.44 Weak + ) +
AM942 USA800 0.44 Weak + ) +
HC476 USA800 0.18 – + ) +
HC568 USA800 0.26 Weak + ) +
HC653 USA800 0.21 Weak + ) +
HC753 USA800 0.14 – + ) +
AM588 BEC 0.97 Strong ) ) +
AM833 BEC 1 Strong ) ) +
AM898 BEC 1.1 Strong ) ) +
AM905 BEC 1 Strong ) ) )
AM932 BEC 0.93 Strong ) ) +
AM953 BEC 1 Strong ) ) +
aExpressed in bioﬁlm units (see Materials and methods).
bWeak, weak bioﬁlm producer; –, non-bioﬁlm producer; strong, strong bioﬁlm
producer (see Materials and methods).
cAccessory genes tested were sea, seb, sec, sed, seh, sek (staphylococcal enterotoxin A,
B, C, D, H and K genes), egc (enterotoxin gene cluster), lukF (encoding the F subunit
of the Panton–Valentine leukocidin), eta (exfoliative toxin A gene), lukDE (leuko-
cidin DE gene) and lukM (leukocidin M gene). When all the isolates tested were
negative for a particular gene, the column was omitted from the table.
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determining the ﬁtness of speciﬁc pandemic
MRSA clones.
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